Akari

Madhu Kumar of Chardan Capital Markets maintains a Sell rating on Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) ahead of the company's R&D Day on April 24. In a research report published Monday, Kumar highlighted his skepticism surrounding the company's Fast Track designation of Coversin, a...